Pharma Nord ApS - a Scandinavian manufacturer with focus on medicine for cardiovascular diseases based on a Coenzyme Q10 API.
Pharma Nord actively supports science in its efforts to find new treatments or adjunctive therapies with a low risk factor.
More than 100 scientific studies have been carried out using Pharma Nord’s two CoQ10 preparations, Myoqinon and Bio-Quinone.
Myoqinon is registered as a medical drug in several EU countries.
The products have been used in numerous studies, including in the groundbreaking Q-Symbio study that is published in the Journal of the American College of Cardiology.
The products have been assigned an IND.